Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug2295 | LY3819253 Wiki | 0.38 |
drug3195 | Placebo Wiki | 0.04 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
The SARS-CoV-2 infection may behave differently in pregnant and postpartum women in the short and long term. Several risk factors or medication use can interfere on disease' evolution and vertical transmission. Thus, due the current pandemic and the scarcity of scientific studies involving pregnant women with covid-19 or positive serology, combined with the need to elucidate the behavior of this viral infection in pregnant women in our population, this study aims to evaluate the clinical and laboratory evolution, transplacental passage, gestational and neonatal outcomes in pregnancies with positive SARS-CoV-2.
Description: Number of pregnant women with COVID-19 infection assessed with a serology test
Measure: Diagnostic test: SARS-CoV-2 serology Time: 01/07/2021Description: Number of participants with transplacental passage of SARS-CoV-2 assessed by laboratorial analysis of maternal and umbilical cord blood
Measure: Laboratorial analysis of maternal and umbilical cord blood Time: 01/07/2021Description: Number of participants with transplacental passage of SARS-CoV-2 assessed by amniotic fluid analysis
Measure: Laboratorial analysis of Amniotic Fluid Time: 01/07/2021Description: Number of participants with transplacental passage of SARS-CoV-2 assessed by placenta biopsy
Measure: Placenta biopsy Time: 01/07/2021Description: Number of participants with transplacental passage of SARS-CoV-2 assessed by colostrum
Measure: Laboratorial analysis of colostrum Time: 01/07/2021Description: Number of participants with transplacental passage of SARS-CoV-2 assessed by ovarian remains biopsy in cases of abortion and fetal death.
Measure: Ovarian remains biopsy Time: 01/07/2021Description: Number of participants with adverse events assessed by the blood count analysis after SARS-CoV-2 infection.
Measure: Blood count analysis Time: 01/07/2021Description: Number of participants with adverse events assessed by the thyroid hormones analysis after SARS-CoV-2 infection.
Measure: Laboratorial analysis of thyroid hormones Time: 01/07/2021Description: Number of participants with adverse events assessed by the PCR analysis after SARS-CoV-2 infection.
Measure: PCR analysis Time: 01/07/2021Description: Number of participants with adverse events assessed by the interleukins analysis after SARS-CoV-2 infection.
Measure: Laboratorial analysis of Interleukins Time: 01/07/2021Description: Number of babies with developmental changes and fetal morphology alterations assessed by ultrasound after the maternal diagnosis of Covid-19.
Measure: Fetal morphology ultrasound Time: 01/07/2021Description: Number of participants with placental insufficiency and altered fetal well-being assessed by ultrasound after a positive maternal diagnosis of SARS-CoV-2.
Measure: Placental insufficiency ultrasound Time: 01/07/2021Description: Number of patients that performed natural delivery or caesarean, assessed by a structured questionnaire.
Measure: Type of delivery Time: 01/07/2021Description: Gestational age at delivery and premature cases, assessed by a structured questionnaire.
Measure: Gestational age at delivery Time: 01/07/2021Description: Newborn's apgar score at first, second and third minutes after birth, assessed by a Apgar Score Scale (0 = minimum value and 10 = maximum value)
Measure: Apgar score Time: 01/07/2021Description: Newborn's weight immediately after birth, assessed by a pediatric weight balance
Measure: Newborn weight Time: 01/07/2021Description: Number of patients with persistent symptoms of fatigue, assessed by a Fatigue Structured Scale
Measure: Fatigue Scale Time: 01/07/2021Description: Number of patients who needed intervention with a prone position during hospitalization, accessed by the medical record data.
Measure: Prone Position Time: 01/07/2021Description: Number of patients who needed intervention with a mechanical ventilation and oxygen during hospitalization, accessed by the medical record data.
Measure: Use of mechanical ventilation Time: 01/07/2021Description: Number of patients with alterations in pulmonary ultrasound and chest tomography resulting from SARS-Cov2 infection.
Measure: Pulmonary Ultrasound Time: 01/07/2021Description: Number of patients with alterations in pulmonary ultrasound and chest tomography resulting from SARS-Cov2 infection.
Measure: Chest Tomography Time: 01/07/2021Description: Number of patients with anxious and depressive symptoms in prenatal and postpartum, assessed by Hospital Anxiety and Depression Scale.
Measure: Anxious and depressive symptoms - HAD questionnaire Time: 01/07/2021Description: Number of patients with cardiac autonomic modulation, assessed by a heart rate variability electrocardiogram.
Measure: Heart rate variability electrocardiogram Time: 01/07/2021Description: Number of patients with endocrine system alterations after the Covid-19 infection, assessed by laboratorial analysis of glycated hemoglobin
Measure: Laboratorial analysis of glycated hemoglobin Time: 01/07/2021Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports